101 related articles for article (PubMed ID: 23954217)
1. Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory.
Garcia-Diaz A; Guerrero-Ramos A; McCormick AL; Macartney M; Conibear T; Johnson MA; Haque T; Webster DP
J Clin Virol; 2013 Oct; 58(2):468-73. PubMed ID: 23954217
[TBL] [Abstract][Full Text] [Related]
2. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
[TBL] [Abstract][Full Text] [Related]
4. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM; Conibear T; Hill A; Johnson JA; Tambuyzer L; Thys K; Vingerhoets J; Van Delft Y;
J Antimicrob Chemother; 2014 Apr; 69(4):1090-7. PubMed ID: 24284781
[TBL] [Abstract][Full Text] [Related]
5. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Todesco E; Rodriguez C; Morand-Joubert L; Mercier-Darty M; Desire N; Wirden M; Girard PM; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2015 May; 70(5):1503-6. PubMed ID: 25614045
[TBL] [Abstract][Full Text] [Related]
6. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
[TBL] [Abstract][Full Text] [Related]
7. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
[TBL] [Abstract][Full Text] [Related]
8. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory.
Avidor B; Girshengorn S; Matus N; Talio H; Achsanov S; Zeldis I; Fratty IS; Katchman E; Brosh-Nissimov T; Hassin D; Alon D; Bentwich Z; Yust I; Amit S; Forer R; Vulih Shultsman I; Turner D
J Clin Microbiol; 2013 Mar; 51(3):880-6. PubMed ID: 23284027
[TBL] [Abstract][Full Text] [Related]
11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Vingerhoets J; Rimsky L; Van Eygen V; Nijs S; Vanveggel S; Boven K; Picchio G
Antivir Ther; 2013; 18(2):253-6. PubMed ID: 22951490
[TBL] [Abstract][Full Text] [Related]
14. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
15. Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals.
Bellecave P; Recordon-Pinson P; Papuchon J; Vandenhende MA; Reigadas S; Tauzin B; Fleury H
AIDS Res Hum Retroviruses; 2014 Feb; 30(2):170-3. PubMed ID: 23895115
[TBL] [Abstract][Full Text] [Related]
16. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.
Simen BB; Simons JF; Hullsiek KH; Novak RM; Macarthur RD; Baxter JD; Huang C; Lubeski C; Turenchalk GS; Braverman MS; Desany B; Rothberg JM; Egholm M; Kozal MJ;
J Infect Dis; 2009 Mar; 199(5):693-701. PubMed ID: 19210162
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
[TBL] [Abstract][Full Text] [Related]
18. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.
Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C
J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335
[TBL] [Abstract][Full Text] [Related]
19. Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
Todesco E; Charpentier C; Bertine M; Wirden M; Storto A; Desire N; Grude M; Nguyen T; Sayon S; Yazdanpanah Y; Katlama C; Descamps D; Calvez V; Marcelin AG
HIV Med; 2017 Oct; 18(9):696-700. PubMed ID: 28444829
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.
Aitken SC; Kliphuis A; Wallis CL; Chu ML; Fillekes Q; Barth R; Stevens W; Rinke de Wit TF; Schuurman R
J Clin Virol; 2012 May; 54(1):21-5. PubMed ID: 22306272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
